Cresilon Inc

Cresilon Inc. is a Brooklyn-based biotechnology company specializing in plant-based hemostatic gel medical devices designed to control bleeding rapidly across trauma, surgical, and veterinary applications. Founded in 2010, the company develops flowable hydrogel technology that achieves hemostasis in seconds without manual pressure, addressing critical gaps in hemorrhage control. TRAUMAGEL®, FDA-cleared in 2023, targets emergency medicine, trauma hospitals, military, and law enforcement for moderate to severe external bleeding control. VETIGEL®, launched in 2021, serves the veterinary market and has been used in over 65,000 procedures globally. The technology is composed of plant-derived polymers that adapt to diverse wound geometries, ensuring consistent performance. Cresilon's innovations have earned recognition including a Gold Stevie Award and Fast Company's #1 ranking in medical devices for 2026. The company pursues expanding applications in surgical hemostasis and continues distribution partnerships with major healthcare networks.